Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$1.7B
129M shares
52-week range
$10.32 – $21.50
29% from low
Exchange
NASDAQ
ADRC
Borrow rate
10.55%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.3M | $16.7M | $32.2M | $7.5M | $10.2M | $7.5M | $5.9M | $17.2M |
| Cost of revenue | $5.5M | $75.2M | $81.5M | $85.7M | $63.6M | $54.9M | $41.1M | $5.1M |
| Gross profit | $11.8M | −$58.5M | −$49.3M | −$78.3M | −$53.4M | −$47.4M | −$35.2M | $12.1M |
| Gross margin | 68.2% | -349.5% | -153.4% | -1049.8% | -522.6% | -632.2% | -595.9% | 70.2% |
| R&D | $65.9M | $59.8M | $56.2M | $53.0M | $32.8M | $27.2M | $25.4M | $34.8M |
| Operating income | −$77.3M | −$80.2M | −$74.9M | −$109.1M | −$80.6M | −$69.3M | −$84.1M | −$62.4M |
| EBITDA | −$74.7M | −$84.5M | −$69.0M | −$84.7M | −$76.6M | −$58.5M | −$56.1M | −$73.7M |
| Net income | −$35.3M | −$89.8M | −$77.9M | −$98.8M | −$91.3M | −$81.9M | −$88.0M | −$102.1M |
| Net margin | -203.5% | -537.0% | -242.4% | -1325.3% | -894.6% | -1091.7% | -1490.3% | -593.9% |
| EPS (diluted) | -0.76 | -1.80 | -1.50 | -1.60 | -1.30 | -0.98 | -0.89 | -0.84 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $123M | $-0.34 | $-0.40–$-0.29 | 2 |
| 2027 | $200M | $0.07 | $0.05–$0.09 | 1 |
| 2028 | $303M | $0.72 | $0.56–$0.97 | 1 |
| 2029 | $619M | $2.12 | $1.64–$2.85 | 1 |
Forward consensus · source: Financial Modeling Prep
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
www.mesoblast.comNo one on the platform currently holds MESO.
No tracked institution reports a position in MESO as of their last filing.
| Execution date | Ratio |
|---|---|
| 2024-01-10 | 1-for-2reverse |
No one on the platform has traded MESO yet.
| $2.9B |
| — |
| IBRXImmunityBio, Inc. | $8.71 | +11.81% | $9.1B | — |
| LQDALiquidia Corporation | $78.17 | +1.63% | $7.0B | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 196.3× sales vs its 103.6× historical median P/S.
Fair value ≈ $7.18 · price $13.61 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
The FDA approved $VRDN 's Lumvoa for TED yesterday. Some say it is a minimal threat to $AMGN Tepezza yet the 9 analysts who provide FY30 revenue estimates forecast $850MM to $1.8B in product revenues. VRDN pays 7.5% to DRI Healthcare. The attachment compares VRDN multiples to peer new commercial-stage non-oncology focused bios with 1st approvals over the last 12 months. Only $MESO trades at a lower multiple but there are only multiple analysts providing estimates after FY28. $CYTK & $ARWR are clearly the multiples to aspire to. The multiples may appear high but remember ACLX, NUVL & TERN. This is not investment advice as the comps may be apples to bowling balls.
View on StockTwits ↗$MESO Trailing twelve-month revenue exceeded $65 million, up more than 1,000% year-over-year””
View on StockTwits ↗@Whickdog I think if they do a secondary listing, reverse split is not needed. In that case, the price will be 10x at NASDAQ to its price at ASX Example: $MESO (NASDAQ) vs $MBLTY
View on StockTwits ↗$MESO looks like a future champion,anyone knows another bargain in biotech,pharma with cl phae 3 candidates? Thx in advance
View on StockTwits ↗$INMB $INMB $KRYS $MESO $NVAX $MRNA There is NO reason why InmuneBio is less than $ 3 right now It is trading at 1.5 right now . Fire sale!!
View on StockTwits ↗$INMB $INMB $ABEO $KRYS $MESO $IBRX We are in the eye of the storm . Volume already way up. This is the calm before tomorrow Booyah! Wake up people! 🔥 🔥 INMB 🔥 🔥
View on StockTwits ↗$INMB $INMB expands collab with Anthony Nolan charity for umbilical cord tissue supply to advance CORDStrom hucMSC platform — targeting RDEB (CORDStrom-col7a), solid tumors (TRAIL), OA & more. Prepping for commercial approval! Strong supply deal + regulatory momentum in hot cell/gene therapy & rare disease space. $ABEO $KRYS $MESO $IBRX #biotech #celltherapy #RDEB https://www.stocktitan.net/news/INMB/i-nmune-bio-and-anthony-nolan-announce-strategic-expansion-of-cord-r715r3sueyi2.html
View on StockTwits ↗$MESO headline after the AH close. Mesoblast Reports Ryoncil® Net Revenues of US$30.3M and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million
View on StockTwits ↗$MESO Mesoblast reported fiscal third-quarter net revenue from Ryoncil of US$30.3 million on gross sales of US$35.3 million. Net operating cash spend narrowed to US$4.1 million, supported by receipts of US$34.6 million. Cash on hand totaled US$122 million at March 31, 2026. Patient recruitment target was reached in pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain. Exclusive worldwide license was secured for patented CAR technology platform to develop precision-enhanced MSC products.
View on StockTwits ↗$MESO (+2.5% pre) Mesoblast completes patient recruitment for phase 3 chronic back pain trial https://ooc.bz/l/100328
View on StockTwits ↗$MESO Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain "achieved its patient recruitment target. This marks a significant milestone in Mesoblast's plans for commercialization of rexlemestrocel-L, its proprietary allogeneic stromal cell therapy targeting inflammatory processes underlying disc degeneration."
View on StockTwits ↗🔍 𝗙𝗥𝗘𝗦𝗛 𝗕𝗨𝗬𝗦 🔎 Among the 𝗟𝗮𝗿𝗴𝗲𝘀𝘁 𝗜𝗻𝘀𝗶𝗱𝗲𝗿 𝗕𝘂𝘆𝘀 in the past week: $NKE - $ 2.2M $LW - $ 6.4M $CHPT - $ 250k $MESO - $ 26.2M Nike being the most notable one especially by who the Insiders were who bought. Source: https://hedgefollow.com/largest-insider-buys.php
View on StockTwits ↗$MESO MESOBLAST ACQUIRES CHIMERIC ANTIGEN RECEPTOR (CAR) PLATFORM TECHNOLOGY FOR PRECISION-ENHANCED CELL PRODUCTS https://investorsmedia.mesoblast.com/static-files/223699d4-0d65-42f7-9530-f5fe7131a89a
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.